颈动脉支架置入术中单联与双联抗血小板治疗的疗效与安全性
基于血管质量倡议数据库2016至2021年接受经股动脉颈动脉支架置入术(tfCAS)或经颈动脉血运重建术(TCAR)的患者,比较术前不同抗血小板方案与双联抗血小板治疗(DAPT)的疗效与安全性。校正后,与DAPT相比,无抗血小板治疗或单用阿司匹林与卒中/死亡发生率升高相关,P2Y12抑制剂单药治疗则相似;各组间入路相关出血无差异。
要点
- 与DAPT相比,无抗血小板治疗或单用阿司匹林与tfCAS和TCAR后卒中/死亡发生率升高相关。
- P2Y12抑制剂单药治疗的卒中/死亡发生率与DAPT相似。
- 各治疗组间入路相关出血发生率无差异,术前4小时内加用抗血小板负荷剂量未影响结局。
核心结论
- 与DAPT相比,无抗血小板治疗或阿司匹林单药治疗与CAS后卒中/死亡发生率升高相关,应被劝阻为不安全实践。
- P2Y12抑制剂单药治疗与相似的卒中/死亡发生率相关。
- 出血并发症发生率无差异,术前4小时内加用抗血小板负荷剂量未影响结局。
- 总体而言,这些发现支持当前指南推荐CAS前使用DAPT,但也提示P2Y12抑制剂单药治疗可能提供与DAPT相似的血栓栓塞获益。
- 然而,术前即刻抗血小板负荷剂量可能不提供额外的血栓栓塞获益。
研究设计与样本
- 回顾性队列研究,纳入血管质量倡议数据库中2016至2021年接受tfCAS或TCAR的患者。
- tfCAS患者18,570例,TCAR患者25,459例。
- 按术前抗血小板方案分层:DAPT(阿司匹林+ P2Y12抑制剂)、无抗血小板治疗、单用阿司匹林、阿司匹林+抗血小板负荷剂量、单用P2Y12抑制剂、P2Y12抑制剂+抗血小板负荷剂量。
- 抗血小板负荷剂量在CAS前4小时内给予。
- 采用倾向评分和逆概率加权对数二项回归分析院内结局,以DAPT为参照,并校正术中鱼精蛋白使用。
主要发现
- tfCAS患者中,DAPT占70%,无抗血小板治疗占5.6%,单用阿司匹林占10%,阿司匹林+负荷剂量占8.0%,单用P2Y12抑制剂占4.6%,P2Y12抑制剂+负荷剂量占2.9%。
- tfCAS未校正卒中/死亡发生率分别为:DAPT 2.2%,无抗血小板治疗6.8%,单用阿司匹林4.1%,阿司匹林+负荷剂量5.1%,单用P2Y12抑制剂2.4%,P2Y12抑制剂+负荷剂量2.3%。
- tfCAS校正后,与DAPT相比,卒中/死亡发生率:无抗血小板治疗RR 2.3(95%CI 1.7-3.2),单用阿司匹林RR 1.6(95%CI 1.2-2.1),阿司匹林+负荷剂量RR 2.0(95%CI 1.5-2.7);单用P2Y12抑制剂RR 0.99(95%CI 0.58-1.7),P2Y12抑制剂+负荷剂量RR 1.1(95%CI 0.49-2.5)。
- TCAR患者中,DAPT占81%,无抗血小板治疗占2.0%,单用阿司匹林占5.5%,阿司匹林+负荷剂量占3.5%,单用P2Y12抑制剂占4.9%,P2Y12抑制剂+负荷剂量占2.4%。
- TCAR未校正卒中/死亡发生率分别为:DAPT 1.5%,无抗血小板治疗3.3%,单用阿司匹林3.3%,阿司匹林+负荷剂量2.9%,单用P2Y12抑制剂1.2%,P2Y12抑制剂+负荷剂量1.1%。
临床怎么用
- 当前指南推荐CAS前使用DAPT。
- 作者认为无抗血小板治疗或阿司匹林单药治疗应被劝阻为不安全实践。
- 作者认为P2Y12抑制剂单药治疗可能提供与DAPT相似的血栓栓塞获益。
- 作者认为术前即刻抗血小板负荷剂量可能不提供额外的血栓栓塞获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend dual antiplatelet (AP) therapy (DAPT) before carotid artery stenting (CAS); however, the true clinical effect of single AP therapy vs DAPT is unknown. We examined the efficacy and safety of preoperative single AP therapy vs DAPT in patients who had undergone transfemoral CAS (tfCAS) or transcarotid artery revascularization (TCAR). METHODS: We identified all patients who had undergone tfCAS or TCAR in the Vascular Quality Initiative database from 2016 to 2021. We stratified the patients by procedure and identified those who had received the following preoperative AP regimens: DAPT (acetylsalicylic acid [ASA] + P2Y12 inhibitor [P2Yi]), no AP therapy, ASA only, ASA + AP loading dose, P2Yi only, and P2Yi + AP loading dose. The AP loading dose was given within 4 hours of CAS. We generated propensity scores for each treatment regimen and assessed in-hospital outcomes using inverse probability weighted log binomial regression, with DAPT as the reference and adjusting for intraoperative protamine use. The primary efficacy outcome was a composite end point of stroke and death, and the primary safety outcome was access-related bleeding. RESULTS: Of the 18,570 tfCAS patients, 70% had received DAPT, 5.6% no AP therapy, 10% ASA only, 8.0% ASA + AP loading dose, 4.6% P2Yi only, and 2.9% P2Yi + AP loading dose. The corresponding unadjusted rates of stroke/death were 2.2%, 6.8%, 4.1%, 5.1%, 2.4%, and 2.3%. After adjustment, compared with DAPT, the incidence of stroke/death was higher with no AP therapy (relative risk [RR], 2.3; 95% confidence interval [CI], 1.7-3.2), ASA only (RR, 1.6; 95% CI, 1.2-2.1), and ASA + AP loading dose (RR, 2.0; 95% CI, 1.5-2.7) but was similar with P2Yi only (RR, 0.99; 95% CI, 0.58-1.7) and P2Yi + AP loading dose (RR, 1.1; 95% CI, 0.49-2.5). Of the 25,459 TCAR patients, 81% had received DAPT, 2.0% no AP therapy, 5.5% ASA only, 3.5% ASA + AP loading dose, 4.9% P2Yi only, and 2.4% P2Yi + AP loading dose. The corresponding unadjusted rates of stroke/death were 1.5%, 3.3%, 3.3%, 2.9%, 1.2%, and 1.1%. After adjustment, compared with DAPT, the incidence of stroke/death was higher with no AP therapy (RR, 2.0; 95% CI, 1.2-3.3) and ASA only (RR, 2.2; 95% CI, 1.5-3.1), with a trend toward a higher incidence with ASA + AP loading dose (RR, 1.6; 95% CI, 0.99-2.6), and was similar with P2Yi only (RR, 0.98; 95% CI, 0.54-1.8) and P2Yi + AP loading dose (RR, 0.66; 95% CI, 0.27-1.6). No differences were found in the incidence of access-related bleeding between the treatment groups after tfCAS or TCAR. CONCLUSIONS: Compared with DAPT, no AP therapy or ASA monotherapy was associated with higher rates of stroke/death after CAS and should be discouraged as unsafe practice. Meanwhile, P2Yi monotherapy was associated with similar rates of stroke/death. No differences were found in the incidence of bleeding complications, and adding an AP loading dose to ASA or P2Yi monotherapy within 4 hours of the procedure did not affect the outcomes. Overall, these findings support the current guidelines recommending DAPT before CAS but also suggest that P2Yi monotherapy might confer thromboembolic benefits similar to those with DAPT. However, an immediate preoperative AP loading dose might not provide additional thromboembolic benefits.
引用
- Marcaccio CL, Patel PB, Rastogi V, et al. Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting. J Vasc Surg. 2022. PMID: 36581013. doi:10.1016/j.jvs.2022.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。